From the Research
Intravenous DMSO (dimethyl sulfoxide) is not recommended for treating multiple sclerosis (MS). There is no reliable scientific evidence supporting its effectiveness for MS, and it is not an FDA-approved treatment for this condition. The standard treatments for MS include disease-modifying therapies such as interferon beta medications, glatiramer acetate, fingolimod, natalizumab, ocrelizumab, and others that have been clinically proven to reduce relapses and slow disease progression 1.
While DMSO has anti-inflammatory and antioxidant properties that might theoretically address some aspects of MS pathology, its use remains experimental at best and potentially harmful. DMSO can cause serious side effects including allergic reactions, vision problems, and a distinctive garlic-like body odor. Additionally, IV administration of any substance outside medical supervision carries risks of infection, embolism, and other complications.
Some studies have investigated the use of other treatments for MS, such as intravenous immunoglobulin (IVIg) 2 and oral versus intravenous methylprednisolone 3, but these do not support the use of IV DMSO. In fact, the most recent and highest quality studies suggest that established disease-modifying therapies are effective in reducing relapses and slowing disease progression, and that patients with MS should work with neurologists specializing in MS to develop evidence-based treatment plans rather than pursuing unproven therapies like IV DMSO.
Key points to consider include:
- The lack of reliable scientific evidence supporting the effectiveness of IV DMSO for MS
- The potential harm and side effects associated with IV DMSO
- The availability of established, evidence-based treatments for MS
- The importance of working with a neurologist to develop a personalized treatment plan.
Overall, the best approach for managing MS is to use established, evidence-based treatments under the guidance of a neurologist, rather than pursuing unproven therapies like IV DMSO.